Haemonetics Corporation (NYSE:HAE) Q2 2025 Earnings Conference Call November 7, 2024 8:00 AM ET

Company Participants

Olga Guyette - Vice President, Investor Relations and Treasury
Christopher Simon - President and Chief Executive Officer
James D’Arecca - EVP and Chief Financial Officer

Conference Call Participants

Anthony Petrone - Mizuho Securities
Marie Thibault - BTIG
Lawrence Solow - CJS Securities, Inc.
Craig Bijou - BofA Securities
Andrew Cooper - Raymond James
Michael Matson - Needham & Company
Kristen Stewart - CL King

Operator

Good day and thank you for standing by. Welcome to the Second Quarter 2025 Haemonetics Corporation Earnings Conference Call. At this time, all participants are in a listen-only mode. After the speaker presentation, there will be a question-and-answer session. [Operator Instructions] Please be advised that today's conference is being recorded.

I would now like to hand the conference over to your first speaker, Olga Guyette. Please go ahead.

Olga Guyette

Good morning, everyone. Thank you for joining us for Haemonetics second quarter fiscal year 2025 conference call and webcast. I’m joined today by Chris Simon, our CEO; and James D’Arecca, our CFO. This morning, we posted our second quarter fiscal year 2025 results to our Investor Relations website along with our fiscal 2025 guidance.

Before we begin, just a quick reminder that all revenue growth rates discussed today are organic unless specified otherwise, and exclude the impact of currency fluctuation and acquisitions. Our organic revenue growth guidance for fiscal year 2025 incorporates 15 weeks of revenue from OpSens due to the acquisition closing date being in December 2023. We’ll also refer to other non-GAAP financial measures to help investors understand Haemonetics ongoing business performance.

Please note that these measures exclude certain charges and income items. For a full list of excluded items, reconciliations to our GAAP results and comparisons with the prior year periods, please refer to our second quarter fiscal year 2025 earnings release available on our website.

Our remarks today include forward-looking statements and our actual results may differ materially from anticipated results. Factors that may cause our results to differ include those referenced in the Safe Harbor statement in today’s earnings release, and in our usual SEC filings. We do not undertake any obligation to update these forward-looking statements.

And now, I’d like to turn it over to Chris.

Christopher Simon

Thanks, Olga. Good morning and thank you all for joining. Today, we reported second quarter revenue of $346 million, growth of 9% on a reported basis and 4% organically, primarily driven by our hospital business. Year-to-date, revenue growth was 8% reported and 3% organic. Second quarter adjusted earnings per share were $1.12, an increase of 13% from the prior year.